Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235739 · ClinicalTrials.gov registry record · Phase 4
Ancillary Effects of Oral Naloxegol (Movantik)
A Phase 4 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT03235739 is a Phase 4 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 136 participants.
The verdict
NCT03235739, a Phase 4 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether oral Naloxegol can reduce the side effects of opioid painkillers following surgery. This study aims to explore whether Naloxegol can similarly reduce opioid-induced side effects in post-surgical patients. About 130 surgery patients will participate in this study which is being conducted at Cleveland Clinic Main Campus.
Interventions
- DRUG Placebo
- DRUG Naloxegol 25 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03235739
The ClinicalTrials.gov registry entry for NCT03235739 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03235739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03235739 about?
NCT03235739 is a clinical study titled "Ancillary Effects of Oral Naloxegol (Movantik)". The purpose of this study is to find out whether oral Naloxegol can reduce the side effects of opioid painkillers following surgery. This study aims to explore whether Naloxegol can similarly reduce opioid-induced side effects in post-surgical patients. About 130 surgery patients will participate in...
What is the current status of trial NCT03235739?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2017-10-01. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT03235739?
The interventions under investigation include: Placebo (DRUG), Naloxegol 25 MG (DRUG).
Who is sponsoring clinical trial NCT03235739?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.